Suchergebnisse - "Dvorkin, Mikhail"

PubPharm (3)

1

Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN) : updated results from a randomised, controlled, open-label, phase 3 trial

enthalten in: The Lancet. Oncology | 2021

von Goldman, J. | Dvorkin, M. | Chen, Y. | +123

CommentIn: Lancet Oncol. 2021 Mar;22(3):e83. - PMID 33662291

2

Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN) : a randomized, controlled, open-label, phase III study

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2020

von Goldman, J. | Garassino, M. | Chen, Y. | +17

3

Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN) : a randomised, controlled, open-label, phase 3 trial

enthalten in: Lancet (London, England) | 2019

von Paz-Ares, L. | Dvorkin, M. | Chen, Y. | +122

CommentIn: Lancet. 2019 Nov 23;394(10212):1884-1885. - PMID 31590987

1
[1]